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SCAFFOLD COMPOSITION AND ARCHITECTURE CRITICALLY REGULATE
EXTRACELLULAR MATRIX SYNTHESIS BY CARDIOMYOCYTES

ARSELA GISHTO

ABSTRACT

Heart failure accounts for over 5 million cases in the U.S. A major onset of this is
myocardial infarction, which causes the myocardium to loose cardiomyocytes and
transform into a scar tissue. Given that the adult infarcted cardiac tissue has a limited
ability to regenerate, alternative methods to restore the damaged area need to be
developed. The goal of these approaches is to design an optimal scaffold that can retain
and deliver cardiomyocytes at the site of damaged myocardium. This tissue engineering
approach would allow cardiac reconstruction by replacing the lost cardiomyocytes,
delivering the required biomolecules, as well as remodeling the extracellular matrix
(ECM). In this study we investigate the effects of a variety of ECM substrates on the
attachment, survival and ECM production by cardiomyocytes. We cultured rat
cardiomyocytes for 21 days in eleven different substrates, including nanofiber coated
plates and 3D hydrogels. Cell attachment and survival rates were analyzed both
quantitatively and qualitatively. ELISA and fluorometric assays were performed to
quantify the synthesis and release of ECM protein molecules by the cells under various
culture conditions. The matrix protein deposition was also qualitatively analyzed using
immunofluorescence staining and imaging. Finally, the production of MMPs-2, 9 and
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TIMP-1 by these cells was quantified and correlated to matrix synthesis under respective
culture conditions. The observations of this study were that the total protein content
quantified within PCL nanofiber scaffolds was significantly higher compared to that
within hydrogels. Collagen concentration played an important role in cardiomyocyte
survival. Among all cases tested, 2 mg/ml collagen-I (CI-2) provided the highest cell
survival rate. Additionally, laminin-coated PCL nanofiber scaffold provided the most
suitable environment for cardiomyocytes to result in the highest number of beating
cardiomyocytes. However, the maximum beating frequencies were noted in cells cultured
on collagen I and collagen IV coated scaffolds. Taken together, our results suggest that
3D scaffold composition and architecture influences cardiomyocyte phenotype and
matrix protein synthesis, with significant applications in cardiac tissue engineering and
regeneration.
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CHAPTER I

INTRODUCTION

Cardiovascular disease (CVD) is the leading cause of mortality in the United
States and it accounts for over 30% of deaths each year. According to the American Heart
Association (AHA), 83.6 million adults suffer from at least one type of CVD in America.
Besides this enormous number of patients diagnosed with CVD, there is an increase of
28% in treatment procedures in the recent years. This has resulted in a decline of death
rate linked to CVD by 32.7% in a 10 year period (1999-2009). However, the cost
attributed to CVD remains drastically high, over $300 billion. The major contributors to
CVD are hypertension, diabetes mellitus, obesity, increased levels of cholesterol and
myocardial infarction (MI). MI is the leading cause of this high CVD mortality rate.
Approximately 7.6 million of MI cases occur in the U.S. every year1.
MI occurs as a result of ischemia, not enough blood and oxygen supplied to the
myocardium. The infarcted myocardium suffers irreversible damages and loses its cells
permanently. The cardiac muscle then transforms into a scar tissue which leads in an
(ECM) reconstruction, loss of cardiac function, and eventually heart failure. The
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myocardium does not have the ability to regenerate itself and replace the lost
cardiomyocytes. Therefore alternative methods need to be developed to reconstruct the
damaged cardiac tissue and its contractile function. One approach to repair the damaged
myocardium is to replace the lost cardiomyocytes by delivering the required
biomolecules, as well as remodeling the ECM. This tissue engineering approach allows
the delivery of cardiomyocytes by placing a scaffold that mimics the natural cardiac
micro-environment into the infarcted site. During this myocardial regeneration process,
the scaffold needs to be physically and chemically suitable for cardiac myocytes
attachment and survival2,3.
Previous studies have shown that a 3-dimensional (3D) scaffold provides
advantages in cell attachment and proliferation. Additionally, the chemical composition
of the scaffold has a significant role in cell alignment and survival rate. Various types of
synthetic [polycaprolactone (PCL), PCL\gelatin (PG), polyglycolic acid (PGA)] and
biological scaffolds (gelatin, matrigelTM, laminin, collagen) have been developed and
tested in vitro3-6. The synthetic 3D scaffolds can allow for an electrical communication
and synchronized beating between cardiomyocytes7. Previous studies have shown that
aligned nano-fiber scaffolds provide better mechanical properties compared to random
non-aligned ones3. However these 3D scaffolds need to provide biocompatibility with the
cardiac myocytes for higher tissue restoration results. To increase the biocompatibility,
the polymer nanofibers can be combined with naturally occurring proteins. Furthermore
ECM proteins fused together in a 3D architecture can simulate a suitable cardiac
substrate. These tissue engineering approaches can be developed more with a better
understanding of the ECM composites produced by cardiomyocytes. Unfortunately, there
2

is no reported data in literature which analyzed the amounts of ECM proteins synthesized
and deposited by cardiomyocytes within various scaffolds.
To overcome these limitations, we designed this study with the following goals. The
primary objective of this research is to study and understand the effects of scaffold
composition, stiffness and architecture on cardiomyocyte attachment and survival.
Additionally, the second aim of this study is to investigate the role of 3D scaffold
characteristics on extracellular matrix synthesis and deposition by cardiomyocytes. The
matrix molecules quantified in this project are hyaluronic acid (HA), elastin, sGAGs,
LOX, MMPs-2 and 9, TIMP-1.
This thesis is organized as follows:
Chapter II provides an overview of the structure and function of the cardiac
muscle and its extracelluar matrix organization. Also, it provides a summary of the MI
treatment options that are available and in progress, accompanied by a discussion of their
limitations.
Chapter III describes the experimental procedures used for the in vitro culturing
of cardiomyocytes in a variety of 3D biological scaffolds composed of ECM proteins
(collagen types I and IV, laminin, fibronectin) and biodegradable nanofiber scaffolds
(PCL) coated with the ECM proteins. Furthermore, this chapter provides a detailed
description of the quantitative (ELISA and fluorometric assays) and qualitative
(immunofluorescence staining and imaging) analysis of cell survival data and ECM
molecules synthesized and released by the cardiomyocytes.
Chapter IV announces the results obtained from the experiments described in
Chapter III and their interpretation.
3

Chapter V provides conclusions drawn from the results on Chapter IV and an
overview of how the knowledge gained on 3D scaffold composition and matrix synthesis
by cardiomyocytes can be used to design a suitable scaffold that optimizes the attachment
and survival of cardiomyocytes and improves the cardiac function in cases of MI.
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CHAPTER II

BACKGROUND

2.1 Myocardium organization and myocardial infarction

Myocardium is the intermediate layer of the cardiac muscle bordered by
endocardium and epicardium (Figure 2.1 A). The myocardium is composed of contractile
cardiomyocytes assembled in a 3 dimensional fiber network and interstitial space
occupied by fibroblasts, endothelial cells, blood vessels, and ECM. Each individual
cardiac myocyte is surrounded and supported by endomysium, a structure of
fibrocollagenous connective tissue as shown in Figure 2.1 B. Perimysium, a connective
tissue network that encircles bundles of myocytes, supports the shearing forces and
alignment between them (Figure 2.1 B). Any damages in the myocardium reflect in
changes in these supporting extracellular matrices8. An irreversible damage of the cardiac
muscle can be caused by myocardial infarction (MI), also known as heart attack. MI is
caused by a coronary artery blockage due to plaque build-up and thrombosis, blocking
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blood flow to the muscle. The restriction of blood and oxygen supplied to the
myocardium results in cardiomyocyte death, which unfortunately are difficult to replace
or regenerate.

Figure 2.1 (A) Cardiac muscle composed of endocardium, myocardium and epicardium.
(B) 3D structure of cardiomyocytes surrounded by endomysium and perimysium8.

During MI, the number of cardiomyocytes is drastically reduced in the infarcted
area which results in a reduction of cardiac function9. The cell death in MI is followed by
an inflammatory response caused by the migration of macrophages, monocytes, and
neutrophils to the damaged area of the myocardium. This damage continues and expands
with the production of matrix metalloproteinases that have the ability to degrade the
ECM and could lead to an increase of irregular and disorganized collagen deposition. The
ECM changes result in a non-elastic matrix trapping the cardiomyocytes and causing
misalignment and impairment of electrical conductivity between the cells, causing a
continuance in cell death. The lack of blood supply to the myocardium during acute MI
6

causes permanent necrosis and ECM remodeling. This is followed by the formation of
scar tissue in the myocardium damaged area and eventually resulting in heart failure10.
Figure 2.2 shows the disturbance occurring in cellular level of the myocardium during
MI. Studies has shown the presence of poly(ADP-ribose) polymerases (PARPs) during
MI, which are activated during ischemia and continue to be deposited during MI11.
PARPs are responsible for the activation of inflammatory pathways and draining of
cellular energetic pools which lead to cell necrosis11. The inhibition of PARPs can be a
first step in delaying and preventing chronic MI damages that can be life threatening. The
infarcted zone needs to be treated and repaired properly to allow regain of normal
physiology11.

Figure 2.2 Immunofluorescence staining of myocardium for Poly(ADP-ribose) (PAR), an
indicator of PARP activation. The healthy myocardium shows normal cells not stained for
PAR. The area at risk (AAR) of MI shows severely distressed cells and PAR staining.
Infarcted area shows necrotic myocytes with abundant PAR staining11.
7

2.2 Surgical and pharmacological approaches for MI treatment

Due to the enormous number of CVD and heart failure cases, considerable
research has been done for cardiac repair and cardiac muscle regeneration over the past
decades. The primary option in decreasing MI prevalence is their prevention by
controlling the underlying risks. In patients suffering from hypertension, high levels of
cholesterol, obesity, diabetes mellitus, and/or that are genetically prone to cardiac issues,
it is essential that they take the proper medications and follow the right lifestyle to keep
their conditions under control. Other options to treat cardiac diseases and prevent further
damages include drug delivery, use of certain devices and surgery. Depending on the
factor that caused the cardiac dysfunction, the treatment options can vary.
Drug delivery is a method used to provide the required medications in the right
dosage to treat certain conditions. Angiotensin-converting enzyme (ACE) inhibitor is one
type of medication that can be used in cases of left ventricular systolic dysfunction or
after the occurrence of acute MI to prevent or help manage heart failure12. However this
medication has many side effects such as renal insufficiency and hypertension. It can be
combined with diuretic drugs to control fluid accumulation in patients with congestive
heart failure. A wider range of cardiovascular conditions can be treated with beta-blocker
medications that can reduce and prevent further symptoms when inhibited in the right
dosage. A few other examples of drugs used in cardiac dysfunctions are nitrates, antithrombotic agents and nesiritide12.
In cases of coronary artery disease, stents can be inserted to enlarge the blocked
blood vessels. This procedure is known as angioplasty, but not always applicable in
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vessels of smaller sizes. However, bypass surgery can be used as another treatment option
by placing biological or synthetic vascular grafts in the damaged zone. This procedure
has many limitations such as incompatibility issues13. Pacemakers are other devices that
are used in cases of heart failure to normalize the heart rate and function. Although the
placement of a pacemaker can cause dyssynchrony and further the damage, this can be
resolved by using a bi-ventricular pacemaker. In cases of severe heart failure, the
pacemakers are combined with defibrillators. However, they cannot be used within 40
days of the occurrence of myocardial infarction12. Although pharmacological and surgical
approaches contribute to improvements in cardiac output and functionality, they do not
replace, restore or regenerate lost cells and tissue within the damaged or diseased region
of the heart.
Heart transplantation is the last option that can be used in cases of end-stage heart
failure. If the previously discussed treatment options prove to be unsuccessful, the
transplantation of a new heart is the only left choice. However, there are a few issues
linked with this option. One is the problem of finding a heart donor and the main issue is
the rejection of a new foreign heart by the patient. This has led to a significant death rate
within the first year after surgery. Despite their clinical usage and relevance, the abovementioned treatment methods have many limitations; hence alternative strategies need to
be developed for cardiac repair12.

2.3. Tissue engineering approaches

The goal of current tissue engineering approaches is to improve biocompatibilities
of prosthetic devices and grafts, and to design and develop biomaterials and cell delivery
9

options for cardiac repair and regeneration. Numerous studies have been done so far in
the areas of suitable scaffold development, cell transplantation and stem cell based
therapies, which can be used for treatment of MI. When myocardial damage has
occurred, the main concern is to prevent the infarcted zone from enlarging which could
lead to heart failure. Figure 2.3 presents an overview of some techniques investigated for
potential MI treatment. These tissue engineering approaches can be categorized into in
vitro and in situ techniques. Cellular cardiomyoplasty is an in situ technique where cells
are injected directly in the infarcted myocardium. This was the initial focus of research,
which eventually was expanded to include cell culture, stem cell differentiation and
scaffold development. These approaches were performed in vitro and then optimized for
in situ delivery and implantation in the damaged myocardial area10.

Figure 2.3 Three different treatment options for myocardial infarction. Polymer meshes
sutured around the heart to (a) prevent further damage in the left ventricular (LV) (b)
maintain the structure of LV. (c) Cultured cells on a biomaterial scaffold in vitro and
implanted onto the epicardial surface (d) A biomaterial injected in situ (e) A scaffold
injected in situ delivering cells, growth factors10.
10

A study conducted by Kelly et al. was the first to place a poly(propylene) Marlex
mesh in the infarcted zone in the left ventricular (LV) to prevent the enlargement of tissue
damage14. This approach was expanded further to demonstrate that the reason this patch
could restrain the infarction was due to the blocking of metalloproteinases (MMPs) from
being activated in the surrounding areas by serving as a gate around the infarcted zone of
the myocardium. However, this approach did not change the increased volume of LV
during infarction and scar tissue formation. Another polyester mesh has been fabricated
and used by many research groups as a cardiac support device (CSD). In contrary from
the previous mesh, this CSD can be placed to support both ventricles. This method has
been shown to reduce the levels of MMPs, cardiac hypertrophy and LV volume but result
in right ventricular (RV) dysfunction. Despite their relative benefits, the drawbacks of
these techniques include surgery for implantation, lack of repair and regeneration of the
damaged tissue, and failure to improve cardiac function10.
A possible better approach toward myocardial repair is the development of 3D
biomimetic scaffolds suitable for cell attachment and survival. These scaffolds could be
composed of various biodegradable materials; biological, synthetic or a combination of
both.

2.3.1. 2D substrates
In the 1980’s, significant research was done in understanding the role of the ECM
proteins as cell seeding substrates that can be used in myocardial regeneration. Studies
showed that cardiomyocytes could attach and proliferate on 2 dimensional (2D)
substrates of collagen (type I, II, III, IV, and V), laminin and fibronectin. Adult
11

cardiomyocytes attachment was higher on laminin and collagen type IV, whereas
neonatal cardiomyocytes attached better to fibronectin5,15,16. Since ECM proteins are part
of the native cardiac tissue, they are naturally biocompatible and suitable as cell seeding
scaffolds needed for myocardial regeneration. This is shown by Bird et al. by comparing
cardiomyocyte attachment on several 2D substrates. They cultured the cells on plates
coated with 0.1% gelatin, 4% Fetal bovine serum (FBS), ECM (collagen I, IV), matrigel,
laminin and poly-L-lysine. Also they used uncoated plates as control. The results showed
that laminin and collagen IV provided the highest cell attachment and maintaining their
structure for adult cardiomyocytes. The cells cultured on uncoated plates completely lost
their sarcomere organization2.
To further understand the role of ECM proteins in myocardial repair. Boateng et
al. studied the cell attachment of cardiomyocytes and cardiac fibroblasts on RGD (ArgGly-Asp peptide17) and YIGSR (peptide in β-chain of laminin) synthetic peptides versus
fibronectin and laminin where they naturally occur. The results showed that these
synthetic peptides provided the same cell attachment as fibronectin and laminin. However
they could not support sarcomere formation without the presence of the native ECM
proteins18. Although these substrates provide cell survival and are biocompatible, they do
not provide long term regeneration and can cause more damage with time. Also these
scaffolds are 2D and do not provide the best support for cell morphology and contractile
properties. Hence, 3D scaffolds might be a better option19.

2.3.2. 3D scaffolds

Collagen is among the main proteins used in scaffolds preparation. Given that
12

collagen is a native protein of the cardiac tissue, it is tested in developing various
scaffolds for cell culture20. Evans et al. created a 3D tubular scaffold composed of aligned
collagen I fibers to study the development of cardiomyocytes. The cells aligned with the
shape of the scaffold resembling neonatal phenotype and they expressed their contractile
properties21. Collagen scaffold is proven to be a suitable environment for stem cell
differentiation20. However, the 3D scaffolds need to be developed further to become more
suitable for in vivo transplantation. They need to not only provide survival conditions for
the cells but also enhance their cardiac morphology and withstand their mechanical load.
Therefore, another tissue engineering approach for creating suitable scaffolds for
myocardial repair is being developed by incorporating nanofiber polymers.
Electrospun nano-fibers are being increasingly used to create scaffolds of
biodegradable polymers, so as to mimic natural cardiac ECM features. This tissue
engineering approach provides an essential opportunity of myocardial regeneration. Shin
et al. cultured rat cardiomyocytes in vitro in a five layer scaffold composed of PCL
nanofiber resembling an ECM structure. This scaffold was suspended on wire rings
functioning as passive loads. The cells survived for 14 days and expressed cardiac
properties. They started beating upon 3 days of seeding, gained synchronization and
expressed cardiac proteins (α-myosin heavy chain, troponin I and connexin 43).
However, the cardiomyocytes seeded in the innermost layers in this PCL mesh do not
have the same access to fresh growth medium and might not have survived. Another
limitation of this study is that the thickness of suspended wire ring is not appropriate for
clinical applications7. In separate studies, it has been shown that the coating of PCL
nanofibers with collagen can improve cell attachment and proliferation. A study
13

conducted by Zhang et al. compared two 3D scaffolds made of collagen and PCL
nanofibers using two different techniques. The first was a composite of PCL fibers coated
individually with collagen (Collagen-r-PCL) using a coaxial electrospun technique. The
other scaffold was regular electrospun PCL fibers coated with collagen (collagen-coated
PCL). Collagen-r-PCL showed a significant higher percentage of cell (fibroblasts)
proliferation in in vitro culturing. However the limitation of this study is that the pore size
of the Collagen-r-PCL scaffold might affect cell migration6.
The use of collagen in coating nanofiber composites (poly-lactide-co-εcaprolactone) has resulted in increase of cell attachment and proliferation as well 19. On
the other hand, the uncoated nanofiber composites do not support cell attachment,
according to Zong et al. They conducted a study using scaffolds composed of poly-Llactide (PLLA), polyglycolide-based (PLGA) and a composite of PLLA, PLGA and
polyethylene glycol (PEG). Rat cardiomyocytes cultured in vitro on these scaffolds
expressed a better attachment and proliferation in the PLLA scaffold compared to the
composite ones22. Many other polymers were used and tested in vitro and in vivo but they
have encountered biological (necrosis) and mechanical issues (stiffness, mechanical
unstable) mostly in vivo19. However, an improvement is seen when using aligned
nanofibers in developing a scaffold. They provide better mechanical properties and better
resemble the native cardiac ECM. Kai et al. cultured cardiomyocytes on non-aligned PCL
nanofibers, aligned ones, random PCL/gelatin (PG) nanofibers and aligned ones. The
study showed that aligned PG fibers favored cell attachment and their alignment.
However, for long term repair of the myocardium the scaffold should be composed of the
natural ECM molecules3. Hence, the 3D architecture of cardiomyocytes and the
14

surrounding ECM needs to be deeply understood.

2.3.3. In vivo studies

Many in vivo tests have been done to investigate the outcomes of various
scaffolds in myocardial repair. Gelatin and alginate were used in scaffolds seeded with
cardiomyocytes and implanted in the MI area. The studies showed that the cells survived
and cardiac function was improved to a certain level10. However, the scaffolds should
mimic the natural cardiac environment in porosity, pore size, alignment, texture,
composition, etc. to provide the necessary support for cardiomyocytes and long term
cardiac function improvement. Fibrin sealant (a mixture of blood derived adhesives
mainly fibrin and thrombin,23) is a hydrogel that has been injected directly in the
infarcted area of the myocardium containing bone marrow cells and proved to increase
vascular formation in the damaged tissue24. Similar results were gained from injecting
matrigel directly to the tissue19. Alginate gel is another injectable material that was tested
in vivo and showed cardiac improvement25. These materials help maintain shape of the
myocardium, induce angiogenesis (neocapillary formation) and deliver cells or growth
factors. Additional hydrogels that have similar properties in cardiac tissue repair are
collagen, fibrinogen, gelatin, chitosan, hyaluronic acid to name a few19. Poly(ethylene)
glycol (PEG) can be a suitable hydrogel for myocardium regeneration due to its
viscoelastic properties and the fact that its physical and mechanical properties can be
easily adopted during its polymerization. Dobner et al. performed an in vivo study using
PEG hydrogel immediately following MI. This hydrogel provided myocardial remodeling
initially but it did not provide long term repair26,27.
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Many other in vivo studies tested different hydrogels for their ability to help repair
the infarcted myocardium. Zimmerman et al. cultured cardiomyocytes within a 3D gel
composed of collagen type I, matrigel and growth medium of 1-4 mm thickness. This
scaffold was transplanted in the rat heart and performed contractions up to 18 days by
improving the cardiac function. However the drawback of this study is that this
engineered heart tissue experienced a decrease in thickness due to probably necrosis
being developed within the artificial tissue10,28. The 3D scaffolds need to be developed
further to become more suitable for in vivo transplantation. They need to not only provide
survival conditions for the cells but also enhance their cardiac morphology and withstand
their mechanical load.
Despite the wealth of information obtained from such studies, there is a
significant dearth of data in the field of cardiac tissue engineering, specifically on the role
of microenvironment on ECM protein synthesis and deposition by cardiomyocytes. How
do the scaffold properties and characteristics influence matrix production by
cardiomyocytes? What is the composition of the proteins deposited? Are any
inflammatory and matrix-degrading enzymes released by cardiomyocytes? Obtaining
information on these questions is not only crucial to understand cardiomyocyte biology in
vivo, but also to develop tissue engineering and regenerative medicine based approaches
to successfully integrate implanted cardiomyocytes with the native tissue.

2.4 Myocardial extracellular matrix

Cardiomyocytes compose 70-75% of the myocardium volume and are embedded
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in a 3D ECM network of macromolecules. The macromolecules of this matrix are
categorized into sarcomeric proteins, collagenous, glycoproteins, and GAGs. The
sarcomeric proteins (actin, actinin, desmin, and filamin) are synthesized within the
sarcomeres (basic unit of myocytes) that are linked to the subcellular structures via the
help of other proteins such as fibronectin. Fibronectin is a glycoprotein similar to laminin
and has been shown to improve cell attachment. The ECM proteins are essential in
maintaining myocardial structure by providing mechanical support and tensile strength to
the tissue14,15,29-31. Figure 2.4 shows the structure of the main ECM proteins, collagens,
laminin and fibronectin present in the cardiac tissue.

Figure 2.4 The architecture of the main proteins found in the cardiac tissue31.
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Collagens

The major and most abundant protein in ECM is collagen which plays an
important role in providing structure, support and tensile strength in the ECM and blood
vessels. Collagen is presented in many different forms in the cardiac matrix where type I
comprises 80% of the total collagen. Type III accounts for 12% and the remaining of the
collagen volume constitutes of types IV, V, and VI. The collagens have a triple helix
structure constructed with α-chains. The various combinations of the α-chains result in
the different collagen types. For instance, collagen I is composed of two α-1 chains and
one α-2 chain. The triple helix structure of collagen is held stable by the bonds that the
hydroxylated amino acids of proline and lysine (hydroxyproline and hydroxylysine)
form. Collagen I, III and V are fibrillar proteins forming collagenous aggregates to create
collagen fibers. These proteins are found throughout the tissue providing structure and
connecting cardiomyocytes together and to other tissue components such as fibroblasts
and blood vessels. In the cardiac tissue collagen I and III is synthesized by fibroblasts
whereas collagen IV is synthesized by cardiomyocytes. Collagen IV is found abundantly
in the basement membrane of cardiomyocytes and is oriented perpendicular to the other
collagen fibers resulting in a flexible matrix supporting network29-34.

Glycoproteins

Glycoproteins are a crucial part of the ECM. They regulate cell function, help in
cell migration, attachment and proliferation. Fibronectin and laminin are two main
glycoproteins that been shown to provide great attachment for cardiomyocytes14,15,32.
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Fibronectin is a major ECM molecule with a high molecular weight. As shown in
Figure 2.5 A, fibronectin is a dimer composed of two polypeptide chains. This molecule
contains multiple binding sites; it binds to integrins on cellular surfaces and other matrix
molecules such as collagen and heparin. Additionally, fibronectin is present in the ECM
in the form of fibrils which are formed on cell surfaces. Fibronectin has a role in cell
organization and regulating cell function30,32,35. It is found in abundance in the cardiac
tissue in the endomysium31 and it is synthesized in the myocardium by fibroblasts
following MI34.
Another glycoprotein, fibrillin has similar properties with fibronectin. Fibrillin is
the major component of microfibrils and can bind to integrins and other matrix
macromolecules (proteoglycans). The main component of this glycoprotein is cystine and
three isoforms are known up to date. An important role of fibrillin is that it mediates the
assembly of elastic fibers36.
Laminin is another major glycoprotein that is essential in ECM. Specifically, this
protein is found in the basal laminae of the ECM associated with collagen IV. The
molecule of laminin is built by the combination of three polypeptides (α, β and γ; Figure
2.5 B) resulting in a large number of laminin isoforms. Additionally, laminin has the
ability to self-assemble. Similar to fibronectin, this protein has many binding sites for cell
surface molecules and other matrix components such as perlecan (heparan sulfated
proteoglycan) and nidogen. Thus, laminin plays a role in cell organization as well31,32.
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(A)

(B)

(C)

(D)

(E)

Figure 2.5 Structure of ECM molecules. (A) Fibronectin dimer; polypeptides linked by
disulfide bonds. (B) Laminin composed of three different polypeptides chains linked by
disulfide bonds. (C) Sulfated repeating disaccharide unit of GAGs. (D) Non-sulfated
GAG disaccharide unit32. (E) Elastic fiber assembly: (1) tropoelastin cross-linked by
LOX to form elastin polymer, (2) elastin polymer on the cell surface, (3) elastin polymers
transferred to microfibrils through integrins, (4) larger elastin polymer formation, (5)
Elastin polymer cross-linked by LOX to form final elastin protein36.
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Glycosaminoglycans

Glycosaminoglycans (GAGs) are anionic polysaccharides present in the ECM.
They are hydrophilic chains with many disaccharide units. GAGs are divided in two main
groups, sulfates GAGs (sGAGs) and non-sulfated GAGs, depending on whether one of
the sugars is sulfated or not. GAGs are further categorized in four groups; hyaluronan,
chondroitin sulfate, heparan sulfate, and keratan sulfate, based on the type of sugars,
sulfate groups, and their bonding. Figure 2.5 C shows a structure comparison between
sulfated and non-sulfated GAGs. The hyaluronan GAGs known as hyaluronic acid (HA)
lack the sulfated sugar in its disaccharide unit as seen in Figure 2.5 D.
The hydrophilic property of GAGs causes them to expand in the form of gels and
hence occupy a larger volume. This property is beneficial is resisting compressive forces
in the myocardial ECM. Another property of GAGs is to covalently bond to other
proteins forming a structure known as proteoglycans, except of HA. Furthermore, GAGs
play an important role in regulating growth factor signaling activities or serving as coreceptors30,32,37.

Elastin

Elastin is an essential ECM protein which confers elastic properties to blood
vessels, among other functions. This protein is composed of cross-linked soluble
monomers (tropoelastin) forming an insoluble protein mediated by the enzyme lysyl
oxidase (LOX) (Figure 2.5 E). Elastin is assembled into fibers in the muscle tissue with
the assistance of microfibrils, mainly fibrillin. Elastin is majorly synthesized during the
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neonatal developing stages and a significant decrease is noticed in adult stages. This
protein is very important in regulating blood flow due to the elasticity it provides in blood
vessels bearing the mechanical pressure during cardiac cycle. It is shown that elastin
regulates vascular smooth muscle cell proliferation and morphology in damaged cardiac
tissue and prevents their deformation with the help of collagen. Hence, in cases of
myocardial infarction the up regulation of elastin is needed to retain shape36, 38,-40.

Matrix metalloproteinases and their inhibitors

Matrix metalloproteinases (MMPs) are extracellular proteolytic enzymes that
degrade ECM proteins such as collagen, laminin and fibronectin. They are upregulated in
the myocardium during an infarction. Their expression is increased after cardiomyocyte
death to provide room for inflammatory cells. MMPs (1, 2, 3, 8, 9, and 13) degrade the
ECM and the elevated collagen production by breaking down collagen cross-links.
Furthermore, the synthesis of tissue inhibitors of metalloproteinases (TIMPs) is increased
to protect the surrounding non-damaged tissue. These protease-specific TIMPs bind to
the activated proteases during the inflammatory phase. However, during scar tissue
formation MMP-9 and TIMPs are decreased drastically32,34.
.
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CHAPTER III

MATERIALS AND METHODS

3.1 Scaffold preparation

3D hydrogel scaffolds

Six types of 3D hydrogel scaffolds with various compositions were prepared to
evaluate the production and synthesis of ECM proteins by cardiomyocytes, as shown in
Study I of Table3.1 below. Rat-tail derived type-I collagen (3.84 mg/ml; BD Biosciences,
Bedford, MA) was mixed with the appropriate volume of sterile 10 PBS, DI water and 1
N NaOH according to established protocols, to create collagen-I gels with concentrations
of 1.2 mg/ml, 2 mg/ml and 3 mg/ml as detailed below.
To prepare 10 ml of 1.2 mg/ml collagen I, 3.125 ml of collagen I with initial
concentration of 3.84 mg/ml was mixed with 1 ml 10 PBS, 71.9 µl of 1N NaOH and 5.8
ml DI water. To prepare 10 ml of 2 mg/ml collagen I, 5.2 ml of collagen I with initial
concentration of 3.84 mg/ml was mixed with 1 ml 10 PBS, 119.6 µl of 1N NaOH and
3.68 ml DI water. To prepare 10 ml of 3 mg/ml collagen I, 7.8125 ml of collagen I with
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initial concentration of 3.84 mg/ml was mixed with 1 ml 10 PBS, 179.7 µl of 1N NaOH
and 1 ml DI water.
Collagen-I at 2 mg/ml concentration was mixed with 5% type-IV collagen (0.3
mg/ml; human-derived; Sigma-Aldrich, St. Louis, MO), 5% laminin (1 mg/ml; mousederived; Sigma-Aldrich) or 5% fibronectin (1 MG; Sigma-Aldrich) to prepare respective
gels identified in Table 3.1 as detailed below. To prepare collagen-I with 5% type-IV
collagen, 5 ml of collagen-I 2 mg/ml was mixed with 833 µl collagen-IV. To prepare
collagen-I with 5% laminin, 5 ml of collagen-I 2 mg/ml was mixed with 250 µl laminin.
To prepare collagen-I with 5% fibronectin, 5 ml of collagen-I 2 mg/ml was mixed with
250 µl fibronectin.

Table 3.1 Scaffold compositions with respective notations.
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Protein-coated PCL nanofiber scaffolds

Aligned polycaprolactone (PCL) nanofiber matrices (Nanofiber Solutions,
Columbus, OH) were coated with ECM proteins such as collagen-I, collagen-IV, laminin
and fibronectin. Non-coated fibers served as controls. Fiber matrices (fiber diameter ~
700 nm; scaffold thickness ~ 20 microns) were placed within 24-well plates prior to
coating with ECM proteins. Collagen-I and laminin solutions were prepared at 50 µg/ml
concentration each in 0.02 N acetic acid and DI water, respectively. Collagen-IV and
fibronectin were mixed with DI water each for a final concentration of 0.005% and 10
µg/ml, respectively. Collagen-I solution was added to the PCL nanofiber matrices (Study
II in Table 3.1) and incubated at 37 ºC for 1 h. After incubation, the solution was
aspirated and wells were washed with DI water. Similarly, collagen-IV, laminin and
fibronectin were added on the respective wells, left overnight at room temperature (RT),
washed with 1 PBS, and stored.

3.2 Rat cardiomyocytes culture
Neonatal rat ventricular cardiomyocytes (R-CM) (4.0  106) were purchased from
Lonza (Walkersville, MD) and cultured using the supplied medium (RCGM Bulletkit +
5-bromo-2'-deoxyuridine) in accordance with the provided protocol. The growth medium
kit consisted of rat cardiomyocytes basal medium (RCBM), fetal bovine serum, horse
serum, and gentamicin/amphotericin-B antibiotic, which were mixed and sterile-filtered.
5-bromo-2'-deoxyuridine (BrdU) stock solution was reconstituted in 1 ml of basal
medium (40 mM) and sterile-filtered. The thawed cells were gently transferred from the
cryovial into a 15 ml sterile tube, and 2 ml of pre-warmed R-CM media was added
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immediately drop-wise onto the cells while rotating the tube. A 10μl aliquot of the cell
suspension was mixed with an equal volume of Trypan Blue and the viable cells were
counted using a hemocytometer.

Cell culture on 3D hydrogel scaffolds

R-CM were seeded within two different sets of scaffolds as explained in Table 1:
collagen based hydrogels and protein-coated PCL nanofiber scaffolds. Cardiomyocytes
were seeded within hydrogels at a density of ~ 26,000 cells/ well in 48-well culture plates
(Greiner Bio One, Monroe, NC). The gel-laden plates were incubated at 37 ºC for 30 min
to allow for gel polymerization. Similarly, cells were seeded on protein-coated nanofiber
plates at the same seeding density and allowed to attach. In both the cases, four hours
after seeding, media was changed with fresh media. For every scaffold type listed in
Table 1, at least n = 6 wells were cultured to perform each assay detailed in section 2.3.
Cell cultures were performed for 21 days with media changed every three days. The
pooled media was collected and stored at – 20 °C for biochemical assay analysis. At the
end of 21 days, the cell matrices were detached from respective wells by incubating them
with 1 trypsin-EDTA and processed for further analysis.

3.3 Live/Dead Viability/Cytotoxicity assay

The Live/Dead Viability/Cytotoxicity Kit was purchased from Life Technologies
(Grand Island, NY) to perform the viability assay for R-CM survival rate. Initially, the 2
mM EthD-1 stock solution (Component B) was mixed with 1 PBS to create a 4 μM
EthD-1 solution. This solution was mixed with 4 mM calcein AM stock solution
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(Component A) at a 2:1 ratio in accordance with the provided protocol. This EthD1 +
calcein AM solution was vortexed to provide a thorough mixture. At the end of 21 days,
the media was carefully removed from the R-CM cultures (n = 3/hydrogel) and washed
with 1 PBS. Furthermore, they were incubated at 37ºC, 5% CO2 with the EthD-1 +
calcein AM solution. The number of living cells was quantified to achieve the total cell
count and survival rate of R-CM, using Zeiss Axiovert A1 florescence microscope.

3.4 Biochemical analysis

To characterize the ECM synthesized by the cardiomyocytes, several assays
described in the following subsections were performed. These assay were conducted on
cell matrix samples (n = 3 for each scaffold) and pooled media samples (n = 3 per case)
from hydrogels and PCL nanofiber scaffolds (n = 3 for each case). At the end of the 21
day culture, the cell matrices were detached from respective wells by incubating them
with Trypsin 1 for 8-10 minutes. The cell suspensions were transferred to 2 ml
microcentrifuge tubes and centrifuged gently at 2800-3000 rpm for 10-12 minutes. The
supernatant was discarded and the pellet was resuspended in 100-300 μl 1 PBS,
depending on the assay, and stored in -20 °C for further biochemical processing. The
spent media was collected from each well over the 21 day culture period and stored at -20
°C. These pooled media was aliquoted in 2 ml centrifuge tubes and centrifuged at 12000
rpm for 15 min. The supernatant was discarded and the pellet was homogeneously
suspended in 100-300 µl 1 PBS. The samples were stored in -20 °C until further use.

27

BCA assay for total protein synthesis

The total amount of protein synthesized by R-CM was quantified using Pierce
BCA Protein Assay kit (Thermo Scientific, Rockford, IL). The cell matrix and pooled
media samples stored at -20 °C, were thawed and 25 µl of each sample were pipetted in a
96-well plate (Greiner Bio One, Monroe, NC). Standards of 25 µg/ml, 125 µg/ml, 250
µg/ml, 500 µg/ml, 750 µg/ml, 1000 µg/ml, 1500 µg/ml and 2000 µg/ml were prepared
according to the provided protocol and pipetted in the 96-well plate. Additionally, 200 µl
of BCA working solution (WR) was added to each well and mixed on a mechanical
shaker for 30 sec. This BCA WR contains bicinchoninic acid (BCA) which contributes in
the colorimetric capture of Cu1+ reduced from Cu2+ by the total protein present in the
sample. Furthermore, the microplate was incubated at 37 °C for 30 min and cooled at RT
measuring the absorbance at 562 nm on an EpochTM microplate spectrophotometer (BioTek, Winooski, VT). The amount of protein measured was normalized to the total count
of attached and survived cells.

sGAG assay

The sGAG Assay (Kamiya Biomedical Company, Seattle, WA) was used to
quantify the amount of sulfated glycosaminoglycans deposited in the cell matrix and the
pooled media under the various culture cases. A volume of 50 µl in duplicate of
standards, blanks, controls, and samples was diluted with 50 µl of 8M Guanidine-HCl
(GuHCl) and incubated for 15 min at RT. A diluent composed of 0.3% H2SO4 and 0.75%
Triton X-100 (SAT) was added to each vial (50µl), mixed and incubated at RT for 15
min. Furthermore, 750 µl of Alcian Blue working solution was used in each vial to allow
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the dye Alcian blue at a low pH, to bind to the sGAGs. The vials were incubated
overnight at 4°C and the following day they were centrifuged at 12000g for 15 min. The
supernatant was carefully removed using a syringe and the pellet was suspended in
500 µl DMSO solution and mixed on a mechanical shaker for 15 minutes. The
centrifugation was repeated at 12000 g for 15 minutes and the supernatant was discarded.
Finally, 500 µl of Gu-Prop (4M GuHCl + 33% 1-propanol + 0.25% Triton X-100) was
used to dissolve the pellet. The samples were loaded on a 96-well plate and the
absorbance was read at 620 nm using the microplate spectrophotometer. The data were
normalized to the corresponding total cell counts.

Hyaluronic acid assay

The amount of hyaluronic acid (HA) synthesized in the cell matrix as well as
released in the pooled media was quantified using HA-ELISA kit (Echelon, Salt Lake
City, UT). This assay is based on the quantitative enzyme-linked immunoassay technique
where HA binds to a specific enzyme-linked antibody. A volume of 100 µl samples and
standards were pipetted in the provided 96-well incubation plate. The same amount of 1
HA diluent was pipetted serving as a zero HA control, whereas 150 µl of diluent was used
as a blank control. The diluted HA Working Detector (50 µl) was added to all wells
except the blank ones. The plate was gently mixed and incubated for an hour at 37 °C.
After incubation, 100 µl solution was transferred from each well to corresponding wells
in the pre-coated HA detection plate. The plate was incubated for 30 min at 4 °C.
Following incubation, the plate was washed four times with 1 wash concentrate and it
was inverted on absorbent paper to assure total removal of the wash concentrate. An
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amount of 100 µl of working enzyme was added to each well, mixed by gently tapping on
the plate and incubated for 30 min at 37 °C. The washing procedure was repeated after
incubation and 100 µl of working substrate solution was added to each well. The
detection plate was incubated in dark at RT for 15 min and the absorbance was measured
at 405 nm every 15 min until the ratio between the zero HA control and 1600 ng/ml HA
standard is higher than 3. This ratio indicates that incubation is complete and stop
solution is added to each well. The data were normalized the respective cell counts.

Fastin elastin assay

The amount of tropoelastin produced in cell matrix and in pooled media, was
quantified using Fastin Elastin Assay (Accurate Scientific Corp, Westbury, NY, USA).
The samples stored at -20 °C were thawed and processed further to convert the insoluble
elastin into soluble α-elastin form. Therefore the samples were heated at approximately
100 ºC with 1 M oxalic acid for 1 h. The samples were transferred to 2 ml
microcentrifuge tubes and an equal volume of elastin precipitating reagent was added.
Additionally, a 1:1 ratio of elastin precipitating reagent was added in blanks and
standards (12.5 µl, 25 µl, and 50 µl). All samples and standards were run in duplicate and
in accordance to the Fastin elastin assay protocol. Further, each tube was vortexed and for
15 min the reagent was allowed to help precipitate the elastin. The tubes were centrifuged
at 10,000g for 10 min and the supernatant was discarded. The elastin precipitate was
suspended in 1 ml dye reagent and homogeneously mixed. The dye reagent was left to
bind to elastin for a period of 90 min on a mechanical shaker. Following this process, the
tubes were centrifuged at 10,000g for 10 minutes and the supernatant was discarded. Dye
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dissociation reagent (250 µl) was added to each tube and the pellet was dispersed by
vortexing twice with a 10 minutes interval. Finally, the volume of each tube was
transferred in a 96-well microplate and the absorbance was measured at 513 nm with the
microplate spectrophotometer. The data were normalized to the total cell counts.

LOX functional activity

The activity of LOX in the cell matrix and pooled media was quantified with
Amplex® Red Hydrogen Peroxide/Peroxidase assay kit (Molecular Probes, Eugene, OR).
The thawed samples and prepared standards (0, 2, 4, 6, 8, and 10 µM) were pipetted (50
µl) in a 96-well microplate and the same volume of 50 µl of working solution (100 µM
Amplex Red reagent, 1:2, 0.2 U/ml Horseradish peroxidase) was added to each well. The
microplate was incubated in the dark at RT for 30 minutes. During the incubation period
the working solution complex reacted with hydrogen peroxide (H2O2) released when
LOX oxidatively deaminates alkyl monoamines and diamines. Following incubation, the
absorbance of this enzyme activity was measured at 560 nm and final data were
normalized according to the corresponding cell counts.

Quantification of MMP-2 and TIMP-1

The amount of MMP-2 and TIMP-1 released by R-CM in the spent collected
media was determined using MMP-2 ELISA and TIMP-1 ELISA assay, respectively
(Boster Biological Technology Co., Fremont, CA). The same provided protocol
procedure was followed in both assays. Initially, the samples were diluted 2:1 with
provided diluent buffer. Further, 100 µl of each sample was pipetted in the corresponding
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MMP-2 and TIMP-1 specific antibody pre-coated 96-well plates. The respective
standards were pipetted (100 µl) in the respective plates as well. The microplates were
covered and incubated at 37 °C for 90 min. Following incubation process, the content
was removed and they were carefully blotted on absorbent paper without allowing the
wells to dry. The incubation step was repeated with biotinylated anti-rat MMP-2 and
biotinylated anti-rat TIMP-1 antibody working solutions (100 µl per well) at 37 °C for an
hour. The solution was discarded from each plate and the plates were washed three times
with 1 PBS. The plates were incubated with 1 Avidin-Biotin-Peroxidase Complex
(ABC) (100 µl/well) for 30 min at RT followed by washing with 1 PBS five times to
assure the total removal of any residues. TBM color developing agent was added, 90 µl
per well and the plates were incubated at 37 °C for 25-30 minutes before the reaction was
terminated with 100 µl of TMB stop solution in each well. The absorbance was
determined at 450 nm and the sample data were normalized to the total cell count.

Quantification of MMP-9

MMP-9 ELISA assay (R&D Systems, Minneapolis, MN) was used to quantify the
amount of this metalloproteinase that R-CM released in spent pooled media. This assay is
based on the quantitative enzyme-linked immunoassay method where the MMP-9 binds
to a specific monoclonal antibody and a specific enzyme-linked polyclonal antibody, the
same technique followed by the previously presented MMP-2 and TIMP-1 assays.
Initially, 50 µl of diluent RD1-34 was pipetted to each well in the provided pre-coated
96-well plate. The same volume of standards and samples was added to the
corresponding wells and the covered plate was incubated for two hours at RT. Further, the
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wells were washed with wash buffer five times and 100 µl of MMP-9 conjugate was
added to each well. The plate was incubated at RT for another two hours and the washing
step was repeated after incubation. Substrate solution was added, 100 µl per well, and the
plate was incubated in the dark at RT for a shorter time of 30 min. Finally, 100 µl of stop
solution was pipetted to each well and the absorbance was measured at 450 nm and 570
nm. The second values were subtracted from the first ones according to the protocol and
the final data was normalized to the total R-CM count.

3.5 Immunofluorescence analysis

Immunofluorescence labeling was performed to qualitatively identify the presence
of elastin, laminin, α-actinin, fibrillin and LOX in the cell matrix (Table 3.2). At the end
of 21 days the culture wells were washed with 1 PBS and fixed in ice cold 4%
paraformaldehyde (PFA) for 10 minutes (n = 2 per case). The PFA solution was removed
and the cultures were washed with ice cold 1 PBS for 5 minutes. They were incubated
with blocking agent [0.1% Triton-X, 5% goat serum (Sigma-Aldrich), 1X PBS] at RT for
20 minutes. Primary antibody solutions (1% antibody in 1X PBS, 5% goat serum, 0.1%
Triton-X) were added directly to the respective cultures that were incubated overnight at
4 ºC. The culture plates were kept on a mechanical shaker to assure complete antibody
binding. Primary antibody solutions were removed and culture wells were washed 3
times with 1 PBS, 5 min per time. Secondary antibody (Table 3.2) solutions (0.4%
antibody in 1 PBS, 5% goat serum, 0.1% Triton-X) were added and cultures were
incubated for 20 min in dark at RT. Cultures were washed following the procedure
mentioned above. At last, 4’,6- diamino-2-phenylindole dihydrochloride (DAPI; Sigma-
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Aldrich) was added to stain the cell nuclei. After removing the DAPI, 1X PBS was added
to the cell cultures to preserve them while performing florescence imaging using the
Zeiss Axiovert A1 florescence microscope.

Table 3.2 Summary of antibodies used for immunofluorescence analysis.
Primary antibody

Host

Clonality

Concentration
(v/v)

Alpha-actinin

Rabbit

Polyclonal

1;100

Elastin

Rabbit

Polyclonal

1;100

LOX

Rabbit

Polyclonal

1;100

ELR

Rabbit

Polyclonal

1;100

Fibrillin

Rabbit

Polyclonal

1;100

Primary antibody

Host

Clonality

Concentration
(v/v)

Goat anti-Rabbit

Goat

Polyclonal

1;250

3.6 Scanning electron microscopy

To visualize the structure of cardiomyocytes alignment along the nanofibers, the
five cases of nanofiber coated scaffolds were imaged using a scanning electron
microscopy (SEM). The nanofiber coated layers with attached cells were cut out and
passed through a graded series of ethanol concentrations to dehydrate the cell matrix. The
initial ethanol concentration used was 50% and it was increased by 10% up to the final
concentration of 100%. In each dehydration step, the samples were soaked in ethanol for
10 minutes. Furthermore, samples were allowed to air dry for 30 minutes and were
mounted on carbon tape and placed in Sputter machine (SPI sputter model 13131) where
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they were coated in gold for 2 min. Samples were then imaged in the SEM (Amray 1820
using a IXRF 500 digital processor) using 10 KeV electron source at 500 and 1250
magnification.

3.7 Contractile properties of R-CM in PCL nanofiber scaffolds

The ability of R-CM to express their contractile properties was quantified in all
five various PCL nanofiber scaffolds. Videos of contracting cells were recorded using the
florescence microscope and Apowersoft Free Screen Recorder. The data was processed to
quantify the number of beating cells, as well as their frequency across the five different
cases.

3.8 Statistical analysis

All biochemical data obtained were analyzed using Sigmaplot and with the
appropriate functions in MS Excel. Statistical significance values between experimental
conditions were analyzed using Student’s t-test and one-way ANOVA. Variance between
data was considered significant at p < 0.05.
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CHAPTER IV
RESULTS AND DISCUSSION

This chapter will present the data obtained from both sets of experiments. As
described in Chapter III, neonatal rat cardiomyocytes were cultured in vitro for 21 days in
six different 3D hydrogel scaffolds (CI-1.2, CI-2, CI-3, CI + CIV, CI + Lam, CI + Fib), as
well as in five different aligned PCL nanofibers coated with the ECM proteins (collagen
I, collagen IV, laminin, fibronectin) including an uncoated PCL nanofiber plate as control.
Cell survival rate and ECM synthesis were analyzed both quantitatively and qualitatively
and are presented in the following sections.

4.1 Hydrogel scaffolds

4.1.1 Live/Dead Viability/Cytotoxicity assay

The viability assay was performed at the end of the 21 day culture period of the rat
cardiomyocytes. The data for live cell counts are shown in Figure 4.1. Among the three
concentrations of collagen I tested, 2 mg/ml hydrogel provided the highest survival rate
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(91±4%), compared to the other two cases. Collagen hydrogels support most of the
cardiomyocytes to survive and allow them to form a 3D network within the hydrogels
[41]. Increasing collagen I concentration to 3 mg/ml significantly decreased
cardiomyocyte survival rate (72%; p < 0.01 for 3 mg/ml vs. 2 mg/ml; p < 0.01 for 3
mg/ml vs. 1 mg/ml). However, no statistically significant difference in cell survival was
noticed between 2 mg/ml and 1 mg/ml cases. Likewise, a low cell survival rate (77±4%)
was seen in 2 mg/ml collagen I scaffolds, mixed with collagen IV. While coating 2mg/ml
collagen I scaffolds with fibronectin promoted significantly higher cell survival rate
(88±4%) compared to collagen-IV and laminin-coated scaffolds (p< 0.01 in both the
cases), no significant differences were noted between collagen-IV and laminin coated
cases.

Similar effects of fibronectin and laminin 2D substrates on embryonic and

neonatal cardiomyocyte survival, was reported by Evans at al. Fibronectin 2D substrates,
collagen I 2D substrates and collagen 3D scaffolds provided over 85% cell survival rate,
whereas laminin allowed for approximately 55% cell survival21. Taken together, these
results suggest that:
 collagen concentration plays an important role in cardiomyocyte survival, with
higher concentration resulting in more stiffness and less porosity, thereby
decreasing cell survival. An increase in collagen concentration accounts for a
higher mechanical stiffness (G*)42, and
 Coating 2 mg/ml collagen scaffolds with ECM proteins may not benefit
cardiomyocyte survival beyond that offered by un-coated scaffold (e.g.,
fibronectin), and in fact might be detrimental to cell survival (e.g., laminin,
collagen-IV). However, the reasons for this behavior are not clear at this stage and
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needs further investigation.

*

*

*

Figure 4.1 The percentage survival rate of rat cardiomyocytes at the end of 21 day
culture, obtained from Live/Dead Viability assay (n=2). Data was shown as mean ±
standard error.

As shown in previous studies, collagen hydrogels support the majority of seeded
cardiomyocytes to survive and allow them to form a 3D network within the gels41.
However a higher concentration gel causes a decrease in cell survival42. This is due to an
increase in collagen concentration accounting for a higher mechanical stiffness (G*)43.

4.1.2 Biochemical analysis

Total protein synthesis and deposition

The total amount of protein synthesized by cardiomyocytes is divided into two
parts: that deposited within the cell layers in the matrix, and that released in the pooled
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media (Figure 4.2 A). The results obtained from the BCA assay, were normalized to the
total cell count obtained from the viability assay. Data suggests that among the three
different collagen concentrations tested, cardiomyocytes cultured within Cl-2 hydrogel
released the lowest amount of protein in pooled media (p < 0.001 vs. other two cases).
However, cells within this scaffold promoted significantly higher amounts of protein
deposition within cell matrix compared to the other two cases (p < 0.001). Interestingly,
changing the collagen concentration to 1 or 3 mg/ml, significantly increased the protein
content collected in the pooled media (1.68- and 1.54 –fold respectively, compared to CI2). However, these increases in protein release in pooled media could not be translated
into gains in matrix deposition. It was noticed that altering the hydrogel stiffness
significantly decreased the amount of protein deposited in the cell matrix (Fig. 4.2 A).
Mixing the CI-2 scaffolds with collagen-IV or laminin significantly increased the protein
synthesis and release into pooled media (p < 0.001 in both the cases compared to CI-2),
while fibronectin coating did not elicit significant changes (p > 0.1 vs. CI-2). However,
adding laminin significantly reduced protein deposition within cell matrix (p < 0.01 vs.
CI-2) to levels noticed in CI-1.2 or CI-3 scaffolds. The protein deposition into matrix
within fibronectin-mixed scaffolds was the lowest of all the cases (p < 0.01 vs. all the
other cases), while that in collagen-IV mixed scaffolds was comparable to that in CI-2.
Taken together, results suggest that collagen concentration (and therefore stiffness) and
protein addition stimulate varied levels of protein synthesis from rat cardiomyocytes,
with CI-3 and CI+CIV offering the optimal conditions for higher amounts of protein
synthesis.
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Figure 4.2 Protein syntheses by rat cardiomyocytes at the end of 21 day culture (n=3).
Data was shown as mean ± standard error. (A) Total protein synthesized in cell matrix
and released in pooled media on a per cell basis, obtained from BCA protein assay. (B)
Amount of sGAGs synthesized in cell matrix and released in pooled media on a per cell
basis, obtained from sGAG assay. (C) HA content released in pooled media on a per cell
basis, obtained by HA ELISA assay. (D) Elastin synthesized in cell matrix and released in
pooled media on a per cell basis, obtained by Fastin Elastin assay. (E) LOX content
released in pooled media on a per cell basis, obtained by Amplex® Red Hydrogen
Peroxide/Peroxidase assay.
40

Sulfated-glycosaminoglycan (sGAG) release and deposition

The content of sGAGs produced by rat cardiomyocytes varied through the six
cases of hydrogel scaffolds (Figure 4.2 B). The data from the sGAG assay were
normalized to the total cell count within respective cases. It was noted that collagen at 3
mg/ml was the most conducive scaffold for sGAG synthesis and release into pooled
medium as well as deposition into matrix layers, followed by 1.2 mg/ml and 2 mg/ml,
respectively (p < 0.01 for CI-3 vs. CI-1.2 and CI-3 vs. CI-2; p < 0.01 for CI-1.2 vs. CI-2).
Within laminin-coated CI-2 scaffolds, sGAG release into pooled medium remained
unaffected compared to CI-2 cases (p > 0.1), but no quantifiable sGAG presence was
noted within cell layers. Within fibronectin and collagen-IV mixed scaffolds, elevated
levels of sGAG was quantified in both pooled media and matrix, compared to CI-2 gels
(p < 0.01 vs. CI-2). Taken together, data suggests that CI-3 and CI+CIV scaffolds provide
optimal environment for sGAG synthesis, release and deposition in the cell layers.

Hyaluronic acid synthesis and release

The HA-ELISA assay was used to detect the content of HA protein in cell matrix
and in pooled media (Figure 4.2 C), and normalized to cell counts at the end of the 21
day culture. Among the various collagen concentrations tested, CI-3 appeared to offer a
better substrate for HA synthesis and release in pooled media (p < 0.01 for CI-3 vs. CI1.2 and CI-3 vs. CI-2). Quantifiable HA amounts in cell matrix were not detected in all
the cases. Similarly, laminin-coating offered a better substrate for HA release compared
to fibronectin (p < 0.01), although it was not significantly higher than that in collagen-IV
mixed substrates. Nevertheless, dramatic changes in HA synthesis or release was not
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noted with changing concentration or protein-coating.

Elastin synthesis, deposition and crosslinking

The results from the Fastin elastin assay are presented in Figure 4.2 D, with the
amount of tropoelastin (in pooled media) and matrix elastin normalized to the total cell
count. Among all the scaffolds tested, CI-3 followed by CI+CIV, appeared to offer better
conditions for elastin production and deposition. The lowest content of tropoelastin in
both cell matrix and pooled media was assessed in CI-2 hydrogel. These results were in
broad agreement with trends in the sGAGs and total protein synthesis by rat
cardiomyocytes cultured within CI-3 and CI+CIV scaffolds.

Lysyl oxidase enzyme activity within pooled media

LOX activity was measured for each case and normalized to the respective cell
count (Figure 4.2 E). LOX activity in the cell matrix was too low to be accurately
quantified. The cells cultured in CI + Lam and CI + FIB expressed similar amounts of
LOX activity in pooled media, but not significantly higher than that in CI-2. However, a
dramatic decrease in LOX activity was seen in CI + CIV scaffolds. Although no
significant differences in LOX activity were noted between CI-1.2 and CI-2 cases, it was
significantly lower in CI-3 scaffolds (p < 0.01 for CI-3 vs. CI-1.2 and CI-3 vs. CI-2).

Quantification of MMPs-2, 9 and TIMP release

The release of MMP-2 in pooled media was quantified and normalized on a per
cell basis (Figure 4.3 A). The lowest MMP-2 release was noted in CI- 1.2 hydrogel, and
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it progressively increased with increasing collagen concentration (p < 0.01 for CI-3 vs.
CI-1.2 and CI-3 vs. CI-2). Mixing CI-2 scaffolds with collagen IV further increased
MMP-2 release, compared to pure collagen scaffolds. The presence of fibronectin and
laminin appeared to further increase MMP production, compared to adding collagen IV.
Among all the cases tested, the presence of laminin seemed to elicit the highest MMP-2
release. It was interesting to note that the presence of ECM proteins such as laminin,
fibronectin and collagen IV promotes higher release of MMP-2 by rat cardiomyocytes.

(A)

(B)
*

*
*
*

*
*

*

*

(C)
*
*
*

Figure 4.3 Quantification of MMPs and TIMP expressed by rat cardiomyocytes at the
end of 21 day culture (n=3). Data was shown as mean ± standard error. (A) MMP-2
content in pooled media on a per cell basis obtained by MMP-2 assay. (B) MMP-9
released in pooled media on a per cell basis obtained by MMP-9 assay. (C) TIMP-1
content in pooled media on a per cell basis obtained by TIMP-1 assay.
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MMP-9 release by rat cardiomyocytes into pooled media is (Figure 4.3 B)
exhibited different trends compared to MMP-2 release. Collagen-I at 3 mg/ml
concentration promoted significantly higher amounts of MMP-9 release, compared to 1.2
and 2 mg/ml concentrations (p < 0.01 for CI-3 vs. CI-2 and CI-3 vs. CI-1.2). In contrast
to the trends noted for MMP-2 release, addition of collagen-IV, or laminin or fibronectin
drastically reduced MMP-9 release (p < 0.01). Among these 3 proteins, fibronectin
appeared to elicit higher MMP-9 production and release by rat cardiomyocytes.

TIMP-1 synthesis and release by rat cardiomyocytes into pooled media was
normalized to the respective cell count (Figure 4.3 C). Trends in TIMP-1 release were in
contrast to that observed for MMP-9, but similar to those of MMP-2 release. The amount
of TIMP-1 released was in positive correlation to the concentration of collagen I.
Changing the composition of CI-2 hydrogel by adding 5% collagen IV significantly
increased the amount of protease released in pooled media. The addition of 5% laminin or
5% fibronectin, to CI-2 scaffolds, furthered this increase in TIMP-1 production.

4.1.3 Immunofluorescence analysis

The qualitative data obtained from immunofluorescence analysis is presented in
Figures 4.4 and 4.5. The immunofluorescence labeling confirmed the protein synthesis
trends noted in different cultures from quantitative ELISA assays for elastin and LOX.
Immunofluorescence staining was also performed for fibrillin, elastin-laminin receptor
(ELR), and α-actinin proteins, which confirmed the elastin assembly process in respective
cases.
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Figure 4.4 Immunoflourescence images showing staining of rat cardiomyocytes at day
21 for Elastin, Fibrillin and LOX. (n=2; 40x magnification; scale bar = 40 μm).
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Figure 4.5 Immunoflourescence images showing the α-Actinin and ELR staining of rat
cardiomyocytes at day 21. Nuclei are DAPI stained blue. (n=2; 40x magnification; scale
bar = 40 μm)
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4.2 PCL nanofiber coated scaffolds

4.2.1 Live/Dead Viability/Cytotoxicity assay

The percentage of survived cells in each type of nanofiber scaffold gathered from
the viability assay is shown in Figure 4.6. Cardiomyocytes survival on uncoated PCL
nanofiber plates was significantly lower compared to the protein-coated fiber scaffolds (p
< 0.01 for PCL vs. other scaffolds). Kai et al. also reported that cardiomyocytes expressed
higher survival rate in gelatin coated PCL aligned nanofibers compared to uncoated
ones3. Compared to fibronectin, other proteins (laminin, collagen IV and collagen I)
enhanced cell survival (p < 0.01 for PCL+FIB vs. other three proteins).

*

*

*

*

Figure 4.6 The percentage survival rate of rat cardiomyocytes at the end of 21 day
culture, obtained from Live/Dead Viability assay (n=2). Data was shown as mean ±
standard error.
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4.2.2 Biochemical analyses

The total amount of protein synthesized by rat cardiomyocytes was quantified and
normalized on a per cell basis as shown in Figure 4.7 A & B. The cells cultured on PCL
+ FIB scaffolds synthesized higher amount of protein compared to fibers coated with
collagen I, collagen IV, or laminin, in both cell matrix and pooled media. Within cell
matrix, the total protein content in collagen-IV coated fibers was the lowest (p < 0.001),
while that in fibronectin-coated fiber scaffolds was the highest (p < 0.001), compared to
other scaffolds.
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Figure 4.7 Proteins expressed by rat cardiomyocytes at the end of 21 day culture (n=2).
Data was shown as mean ± standard error. (A) Total protein released in pooled media on
a per cell basis, obtained from BCA protein assay. (B) Total protein synthesized in cell
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matrix on a per cell basis, obtained from BCA protein assay. (C) sGAGs synthesized in
cell matrix and released in pooled media normalized to the total protein amount on a per
cell basis, obtained from sGAG assay. (D) HA content in cell matrix and released in
pooled media normalized to the total protein on a per cell basis, obtained by HA ELISA
assay. (E) Elastin synthesized in cell matrix and released in pooled media normalized to
the total protein amount on a per cell basis, obtained by Fastin Elastin assay. (F) LOX
content in cell matrix and released in pooled media normalized to the total protein on a
per cell basis, obtained by Amplex® Red Hydrogen Peroxide/Peroxidase assay.

Figure 4.7 C shows the results from sGAG assay, normalized per µg of total
protein synthesized in respective cases, and further normalized to the total cell count.
Compared to uncoated fibers, coating with collagen IV or laminin significantly improved
sGAGs synthesis released into pooled media (p < 0.001 vs. uncoated PCL fibers).
However, sGAG deposition within cell matrix was significant only within laminin coated
scaffolds. Compared to all the cases tested, laminin coating drastically increased the
synthesis of sGAGs in both cell matrix and pooled media (p < 0.001 for laminin vs. all
other cases). Contrarily, for reasons unclear at this stage, the presence of fibronectin on
the PCL nanofibers dramatically inhibited the synthesis, release and deposition of sGAGs
in the cell matrix and in the pooled media, compared to all the other cases.

HA synthesis was quantified in cell matrix and pooled media and normalized to
the total protein content within respective cases, and further to cell count, as shown in
Figure 4.7 D. Collagen IV-coated PCL cultures expressed the highest amount of HA in
cell matrix and pooled media, compared to controls and all the other cases. The lowest
HA content was observed in collagen I- and fibronectin- coated fiber scaffolds, lower
than that compared to controls (p < 0.01 vs. controls). However, no significant
differences between controls and laminin-coated PCL cultures were noted.
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The amount of tropoelastin synthesized by rat cardiomyocytes within each type of
scaffold was normalized to total protein content and further to the cell count within
respective cases as shown in Figure 4.7 E. Except fibronectin-coated scaffolds where
significant decrease in both tropoelastin and matrix elastin was noted (p < 0.01 vs.
controls), significantly higher tropoelastin and matrix elastin amounts were observed in
all the other three protein coated (collagen I, collagen IV, and laminin) scaffolds. The
LOX enzyme activity was normalized on a per cell basis and is shown in Figure 4.7 F.
LOX enzyme activity was higher in collagen IV-coated PCL nanofibers compared to
controls (p < 0.01). Within the other three protein coated scaffolds, cells deposited a
significantly lower amount of LOX in the cell matrix and in the pooled media (p < 0.01
vs. controls). Among all the cases, fibronectin presence seemed to elicit the lowest LOX
enzyme activity in both cell matrix and pooled media

Quantification of MMPs-2, 9

The MMP-2 production was normalized to the total cell count and the total
protein content and the data is shown in Figure 4.8 A. The presence of collagen I or
fibronectin on the PCL nanofiber scaffolds decreased the content of MMP-2 collected in
pooled media compared to uncoated PCL nanofiber scaffold. However, collagen IV and
laminin increased the content of MMP-2 released in pooled media. Among these proteins,
collagen I inhibited the amount of MMP-2 in pooled media the most, whereas collagen
IV promoted its release the most.

A different trend is noticed in the production of MMP-9 as seen in Figure 4.8 B.
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In all the test cases, where PCL fibers were coated with proteins, significant increase in
MMP-9 release was noted compared to controls (p < 0.01 vs. controls). Laminin-coated
PCL scaffolds promoted the highest MMP-9 release in pooled media.
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Figure 4.8 Quantification of MMPs and TIMP expressed by rat cardiomyocytes at the
end of 21 day culture (n=3). Data was shown as mean ± standard error. (A) MMP-2
content in pooled media on a per cell basis obtained by MMP-2 assay. (B) MMP-9
released in pooled media on a per cell basis obtained by MMP-9 assay. (C) TIMP-1
content in pooled media on a per cell basis obtained by TIMP-1 assay.

Quantification of TIMP-1
The results of TIMP-1 production are presented in Figure 4.8 C. A trend similar
to MMP-9 production was observed in this case. Uncoated PCL nanofibers resulted in the
lowest TIMP-1 content released in pooled media, whereas the ECM proteins expressed
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drastically higher TIMP-1 content. The order of this increase was as follows, collagen I,
collagen IV, laminin and fibronectin accounting for the highest TIMP-1 content.

4.2.3 Immunofluorescence analysis
Immunohistochemistry data showed positive staining for α-actinin, ELR, Elastin,
LOX, and Fibrillin proteins, and the data is shown in Figure 4.9 and 4.10.

Figure 4.9 Immunoflourescence images showing staining of rat cardiomyocytes at day
21 for Fibrillin, Elastin, and α-actinin. (n=2; 40x magnification; scale bar = 40 μm)

Figure 4.10 Immunoflourescence images showing staining of rat cardiomyocytes at day
21 for ELR and LOX. (n=2; 40x magnification; scale bar = 40 μm)
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4.2.4 Scanning electron microscopy

SEM images for each type of nanofiber scaffold are presented in Figure 4.11.
Cardiomyocytes have anchored onto the PCL fibers in each scaffold. While cell body was
not aligned with fiber structure within controls, collagen I and fibronectin-coated PCL
cultures, cells seemed perfectly aligned along the longitudinal axis of the fibers within
laminin and collagen IV-coated nanofibers. This might partially explain the significantly
higher cells survival within these two scaffolds compared to the controls, collagen IV and
fibronectin coated cases.

Figure 4.11 SEM images of rat cardiomyocytes cultured on PCL nanofiber scaffolds.
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4.2.5 Beating cardiomyocytes

The rat cardiomyocytes expressed continuous contractile properties during the 21
day culture on the PCL nanofibrous scaffolds. The number of beating cells and their
frequency was quantified and shown in Figure 4.12. The scaffold with uncoated PCL
nanofibers exhibited the lowest percentage of beating myocytes with the lowest
frequency. Furthermore, coating of these fibers allowed the cells to contract more and at a
higher frequency. Although laminin coated PCL nanofiber scaffold provided the most
suitable environment for cardiomyocytes to exhibit the highest number of beating
cardiomyocytes, the contracting frequency was low. The highest beating frequencies were
noted in cells cultured on collagen I and IV coated scaffolds. These contractile properties
of cardiomyocytes could not be observed within hydrogels.

*

*

*

*
*
*
*

Figure 4.12 (A) Percentage of beating cardiomyocytes over the 21 day culture in five
various scaffolds. (B) Average beating frequency of the cardiomyocytes during the 21 day
culture.
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CHAPTER V

CONCLUSIONS AND RECOMMENDATIONS

In this study, we developed and tested six types of 3D hydrogel scaffolds using the
native proteins of ECM such as, collagen I, collagen IV, laminin and fibronectin.
Additionally, we tested five different aligned PCL nanofibers scaffolds coated with the
same proteins, including an uncoated PCL nanofiber plate as control. Although all these
scaffolds have proved to be suitable for in vitro cardiomyocyte culture by providing cell
attachment, survival, and cardiac phenotype expression, the amounts of ECM proteins
synthesized by cardiomyocytes varied from scaffold to scaffold. The following are the
conclusions from this study.

5.1 Conclusions
 Among all the hydrogels tested, collagen I at concentration of 2 mg/ml (CI-2)
provided the highest cell survival rate and the lowest total protein content released
in pooled media on a per cell basis.
 The increase of collagen concentration to 3 mg/ml resulted in a stiffer scaffold
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decreasing cell survival. However collagen 3 mg/ml (CI-3) expressed the highest
amount of sGAGs and elastin in both cell matrix and pooled media, as well as HA
content in pooled media.
 Opposite trends were noticed between elastin and LOX expression in pooled
media. Given the fact that LOX cross-links tropoelastin monomers to form the
elastin protein, the soluble tropoelastin collected in pooled media is found in
higher content in cases where LOX expression is less and vice versa.
 Overall, the highest total protein amount was synthesized by cardiomyocytes
cultured in CI + CIV hydrogel. However, further studies at the genetic level are
needed to understand how these hydrogels specifically upregulated synthesis and
deposition of ECM proteins such as elastin, HA and sGAGs.
 The collagen-I hydrogels (CI-1.2, CI-2 & CI-3) released low content of MMP-2
and TIMP-1, but drastically higher amounts of MMP-9. The addition of collagenIV, or laminin, or fibronectin showed opposite trends by increasing MMP-2,
TIMP-1 and reducing MMP-9.
 Protein-coated PCL nanofibers provided better cell survival rate compared to
uncoated PCL nanofibers, possibly due to lack of binding sites for cellular
integrins to attach and home in.
 While fibronectin-coated PCL nanofibers contributed to the highest total protein
content in matrix as well as pooled media, collagen IV coating had the opposite
effect. Interestingly, similar trends were noted in the amounts of protein deposited
in matrix and released in pooled media, for all PCL nanofiber cases.
 Cells cultured on laminin-coated PCL fibers expressed the largest content of
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sGAGs and elastin whereas those cultured on collagen IV-coated fibers produced
the highest amount of HA and LOX.
 Hydrogels account for a much higher survival rate of cardiomyocytes compared
to PCL nanofiber coated scaffolds. Among hydrogels, collagen 2 mg/ml is the
most suitable scaffold for culturing cells (91% survival rate). In the cases of PCL
nanofiber scaffolds, laminin-coating provided the best cell survival environment
(42% survival rate).
 In general, the total protein content quantified within PCL nanofiber scaffolds was
significantly higher compared to that within hydrogels.
 While sGAGs released in pooled media was significantly higher within hydrogels
compared to that in PCL nanofiber coated scaffolds, nanofiber scaffolds facilitated
higher fraction of sGAGs to be deposited as matrix. However, opposite trends was
seen in HA synthesis.
 Elastin synthesis was much higher in protein-coated PCL nanofibers compared to
hydrogels.
 TIMP-1 content in pooled media was the highest in fibronectin-coated PCL
nanofibers, followed closely by laminin. The same outcome was noticed in
hydrogels containing fibronectin or laminin (CI + FIB, CI + LAM).

5.2 Recommendations
The following are recommendations for future studies to further understand the effects of
scaffolds on ECM protein production by cardiomyocytes and develop the most natural
cardiac mimicking scaffold.
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 Semi-quantitative Western blot analysis to quantify elastin and LOX proteins
within pooled media.
 Enhance synchronized beating of cardiomyocytes within 3D scaffolds.
 Develop an electrospining setup to produce nanofibers blended with ECM
proteins.
 Quantify changes at the transcription-level (genetic level) for ECM protein
synthesis and deposition within 3D scaffolds.
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